MRK Tredaptive post-mortem: Give the FDA credit for rejecting the Tredaptive* NDA almost five years ago and insisting on an outcomes study even though the prior phase-3 trial using lipid endpoints was nominally a success (#msg-30170058, #msg-28864222).
*f/k/a Cordaptive, MK-0524.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.